Physician

Viralkumar K Bhanderi, M.D.

According to 2025 Medicare claims, Viralkumar Bhanderi, M.D. (NPI: 1265518377) practices medical oncology in the Tallahassee, FL market, with the plurality of this provider's patient population coming from Leon, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32308-5333.

Bhanderi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 341 traditional Medicare patients, billed 104,707 HCPCS/CPT codes, and received $2,333,832 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,668 prescription claims across 253 beneficiaries totaling $4,775,386 in drug costs, led by Brukinsa (Zanubrutinib). 2018 DME data shows 16 claims. Open Payments data shows 168 records totaling $1,036,367. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $2,079,029 and ending at $4,775,386. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	473	97,115	$1,916,912
2016	475	128,748	$2,384,859
2017	502	120,713	$2,694,000
2018	475	126,680	$2,946,800
2019	475	168,748	$2,893,216
2020	446	185,485	$2,996,842
2021	426	141,167	$2,570,324
2022	411	122,737	$2,117,844
2023	374	138,407	$2,215,116
2024	341	104,707	$2,333,832

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	214	1,428	$2,079,029
2016	231	1,602	$3,230,972
2017	244	1,620	$2,945,823
2018	238	1,506	$2,100,191
2019	242	1,599	$3,426,919
2020	244	1,823	$4,474,370
2021	272	1,486	$2,677,482
2022	223	1,142	$2,126,430
2023	241	1,215	$2,792,785
2024	253	1,668	$4,775,386

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	17	$271
2018	N/R	16	$7,840
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	237	629	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	145	198	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	97	147	$13
36415	Insertion of needle into vein for collection of blood sample	298	1,034	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	301	1,097	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	84	2,490	$1,182,277
Revlimid	Lenalidomide	49	1,330	$775,686
Cabometyx	Cabozantinib S-Malate	18	526	$390,422
Calquence	Acalabrutinib Maleate	20	600	$300,974
Venclexta	Venetoclax	32	946	$269,536

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	57	$1,595	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	111	$1,034,772	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Viralkumar K. Bhanderi, M.D.?

Tedicare shows public-source Medicare data for Viralkumar K. Bhanderi, M.D. (NPI 1265518377), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Viralkumar K. Bhanderi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Viralkumar K. Bhanderi, M.D.?

Viralkumar K. Bhanderi, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Viralkumar K. Bhanderi, M.D. have Open Payments data?

Viralkumar K. Bhanderi, M.D. has 168 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.